Zynex (NASDAQ:ZYXI) Issues Q2 Earnings Guidance

Zynex (NASDAQ:ZYXI) updated its second quarter earnings guidance on Tuesday. The company provided earnings per share guidance of $0.08 for the period, compared to the consensus earnings per share estimate of $0.07. The company issued revenue guidance of $52 million, compared to the consensus revenue estimate of $53.13 million. Zynex also updated its FY 2024 guidance to 0.500- EPS.

Zynex Trading Down 4.2 %

Shares of NASDAQ ZYXI traded down $0.48 during trading hours on Tuesday, hitting $10.97. 156,977 shares of the company traded hands, compared to its average volume of 233,517. The stock has a market capitalization of $352.90 million, a price-to-earnings ratio of 40.63 and a beta of 0.48. The company has a current ratio of 4.74, a quick ratio of 4.03 and a debt-to-equity ratio of 1.26. The company’s 50 day moving average price is $12.35 and its 200 day moving average price is $10.83. Zynex has a 12 month low of $6.88 and a 12 month high of $14.75.

Zynex (NASDAQ:ZYXI) last announced its quarterly earnings data on Thursday, February 29th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.17 by ($0.13). The business had revenue of $47.28 million during the quarter, compared to the consensus estimate of $54.53 million. Zynex had a net margin of 5.28% and a return on equity of 16.82%. The business’s revenue was down 3.1% compared to the same quarter last year. During the same period last year, the company earned $0.20 EPS. On average, equities research analysts anticipate that Zynex will post 0.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ZYXI has been the topic of a number of recent research reports. HC Wainwright increased their price target on Zynex from $20.00 to $21.00 and gave the stock a buy rating in a research report on Friday, March 1st. Royal Bank of Canada upped their price objective on Zynex from $13.00 to $15.00 and gave the stock an outperform rating in a research note on Friday, March 1st.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.